What is the primary clinical utility of measuring CEA?

The primary clinical utility of measuring Carcinoembryonic Antigen (CEA) is for monitoring the recurrence of certain types of cancer, particularly colorectal cancer. CEA is a protein that can be elevated in the blood of patients with certain cancers, and its levels can be tracked over time. After a patient undergoes treatment for cancer, regular monitoring of CEA levels can help detect any resurgence or recurrence of the disease, often before clinical symptoms arise.

This usage is particularly valuable because it allows for timely interventions if the cancer reappears, making it a crucial aspect of patient management post-treatment. While CEA levels can also be elevated due to other conditions, its most accepted role in clinical practice is related to monitoring established cancer cases rather than initial diagnosis or screening. This focus on recurrence detection emphasizes the importance of follow-up care in oncology.